CG Oncology, Inc.
CG Oncology, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 54.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 4, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 15, 2026 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Trial Milestone | Phase 3 |
| March 31, 2027 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Trial Milestone | Phase 2 |
| June 16, 2030 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Trial Milestone | Phase 3 |
Track CGON alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CGON in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.